Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
13.50
-0.31 (-2.24%)
At close: Jul 20, 2026, 4:00 PM EDT
13.60
+0.10 (0.74%)
After-hours: Jul 20, 2026, 7:45 PM EDT
Summit Therapeutics Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Summit Therapeutics stock has a consensus rating of "Buy" and an average price target of $28.86. The average 1-year stock price forecast is 113.78% higher than the current stock price, while the lowest is $9.97 (-26.15%) and the highest is $45.03 (+233.56%).
Price Target: $28.86 (+113.78%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Summit Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 10 | 11 | 9 | 9 | 9 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 4 | 4 | 5 | 5 | 5 |
| Sell | 1 | 1 | 1 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 17 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jul 15, 2026 |
| Bernstein | Bernstein | Sell Reiterates $7.7 → $9.8 | Sell | Reiterates | $7.7 → $9.8 | -27.41% | Jun 22, 2026 |
| Barclays | Barclays | Hold Maintains $18 | Hold | Maintains | $18 | +33.33% | Jun 2, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $45 | Buy | Maintains | $45 | +233.33% | Jun 1, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $40 | Buy | Maintains | $40 | +196.30% | Jun 1, 2026 |
Financial Forecast
Revenue This Year
3.29M
Revenue Next Year
56.53M
from 3.29M
Increased by 1,617.29%
EPS This Year
-1.11
from -1.43
EPS Next Year
-1.18
from -1.11
EPS and Forward PE are based on non-GAAP adjusted numbers.